I read this article last year but haven't heard anything since. I am keeping my eyes peeled for some more news on this new 'miracle' gel.
Feel free to take a look. Early tests sound extremely promising
http://www.dailymail.co.uk/pages/live/arti...in_page_id=1965
Darren
Small Glimmer of Hope?
Started by TheseWordsAreMyOwN, Mar 23 2008 08:07 AM
4 replies to this topic
#1
Posted 23 March 2008 - 08:07 AM
#2
Posted 23 March 2008 - 08:52 PM
Sounds promising! Have you found any other info on it?
#3
Posted 25 March 2008 - 12:03 AM
I hope they'll fast track the processing of that pill... Hope springs eternal!!!!
__________________
get rid of acne fast!
__________________
get rid of acne fast!
#4
Posted 27 March 2008 - 12:11 PM
On this website: http://www.oxfordshirebioscience.com/obn_/...=5WEUBRMVAE2535
They said:
SMT D002 is being developed as a novel treatment for seborrhoea (excessive sebum production). Seborrhoea is also believed to be the primary cause of acne and SMT D002 is currently in a Phase I clinical trial with the results expected during Q1 2008.
That's about all I could find on it.
Oh and I just found this:
http://www.summitplc.com/SMT%20D002.htm
According to the second link, it is something that is already available in some form, but they obviously don't want to reveal that at the moment.
They said:
SMT D002 is being developed as a novel treatment for seborrhoea (excessive sebum production). Seborrhoea is also believed to be the primary cause of acne and SMT D002 is currently in a Phase I clinical trial with the results expected during Q1 2008.
That's about all I could find on it.
Oh and I just found this:
http://www.summitplc.com/SMT%20D002.htm
According to the second link, it is something that is already available in some form, but they obviously don't want to reveal that at the moment.
#5
Posted 15 April 2008 - 04:21 AM
MUMBAI (Thomson Financial) - Summit Corp Plc. said it received positive results from a phase I clinical trial of SMT D002, its candidate to treat excessive sebum production, a primary cause of acne.
It reported "significant" levels of sebum suppression of 90 percent compared to the placebo group, and added that no serious or unexpected adverse side-effects were reported.
Summit now plans to develop a topical formulation of SMT D002 -- as part of its programme to find new therapeutic uses for existing marketed drugs -- and is actively seeking a commercial partner to advance this candidate.
It reported "significant" levels of sebum suppression of 90 percent compared to the placebo group, and added that no serious or unexpected adverse side-effects were reported.
Summit now plans to develop a topical formulation of SMT D002 -- as part of its programme to find new therapeutic uses for existing marketed drugs -- and is actively seeking a commercial partner to advance this candidate.
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users



Home











